Why the study?
Does renal denervation benefit patients with chronic kidney disease?
Does renal denervation benefit patients with chronic kidney disease?
Chronic kidney disease may represent a distinct pathophysiological condition particularly suited for renal denervation therapy.
CKD may suit renal denervation due to sympathetic overdrive; leaves open clinical benefit pending randomized trials.
Renal denervation is being used as a blood pressure lowering therapy for patients with apparent treatment resistant hypertension. However, this population does not represent a distinct disease condition in which benefit is predictable. In fact, the wide range in effectiveness of renal denervation could be a consequence of this heterogeneous pathogenesis of hypertension. Since renal denervation aims at disrupting sympathetic nerves surrounding the renal arteries, it seems obvious to focus on patients with increased afferent and/or efferent renal sympathetic nerve activity. In this review will be argued, from both a pathophysiological and a clinical point of view, that chronic kidney disease is particularly suited to renal denervation.
No takes yet. Share an insight, caveat, or question.
Sanders et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: